Moving On from AAV with Poseida Therapeutics' CEO, Mark Gergen

Cell & Gene: The Podcast

English - June 23, 2022 08:00 - 27 minutes - 19 MB - ★★★★★ - 35 ratings
Life Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Inside the New Hybrid Roles for Cell Therapy Clinical Trials with Immatics' Michael Mehler

Next Episode: Inside Gamma Delta T Cells with TC BioPharm’s CEO, Bryan Kobel

Poseida Therapeutics is a broad platform technology company led by CEO, Mark Gergen. During this episode, Gergen explains how and why the company is moving away from AAV delivery in favor of nanoparticle delivery. He shares some of the biggest hurdles the CGT sector faces when it comes to the development of off-the-shelf therapies as well as the manufacturing challenges Poseida has had to overcome and how they did it.